A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin.
Mitchell ClarkAlexandra KollaraTheodore J BrownTaymaa MayPublished in: Journal of ovarian research (2021)
In this animal model, surgical wounding with suboptimal cytoreduction after neoadjuvant chemotherapy did not cause accelerated expansion of residual disease. Surgical wounding appears to impair cisplatin activity when given at time of surgery.
Keyphrases
- neoadjuvant chemotherapy
- minimally invasive
- locally advanced
- coronary artery bypass
- lymph node
- sentinel lymph node
- mouse model
- surgical site infection
- rectal cancer
- cardiac surgery
- squamous cell carcinoma
- percutaneous coronary intervention
- acute kidney injury
- atrial fibrillation
- acute coronary syndrome
- coronary artery disease
- metastatic renal cell carcinoma